Phaseline

Companies › Belite Bio

Belite Bio: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Ophthalmology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tinlarebant (LBS-008)–Phase 3Geographic Atrophy; STGD1Jun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05949593Tinlarebant (LBS-008)Phase 3Geographic AtrophyOphthalmologyJun 2027
NCT06388083Tinlarebant (LBS-008)Phase 2STGD1OphthalmologyFeb 2028

From the company's SEC filings

Cash of $353m on 2025-12-31; operating cash outflow about $37m a year; runway about 114 months at that burn, to Jul 2035; 2 of 2 coming phase 2-3 readouts fall inside that runway

Specialist investors

Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Cloudbreak Therapeutics Omikron Italia S.r.l. Viridian Therapeutics Aurion Biotech Smilebiotek Zhuhai

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.